UK approves Pfizer’s coronavirus vaccine

The UK has become the first country in the world to approve the Pfizer/BioNTech COVID-19 vaccine for use.

It has been given the go-ahead by the health regulator MHRA and will be rolled out from early next week. Studies have shown the jab is 95% effective and works in all age groups. The government has secured 40 million doses of the vaccine, which needs to be refrigerated at -70C (-94F). Ten million doses are expected in the UK by the end of the year and patients need two each. Care home residents and their carers will be first in line to be vaccinated, the government’s Joint Committee on Vaccination and Immunisation (JCVI) has confirmed. Studies have shown the jab is 95% effective and works in all age groups. The government has secured 40 million doses of the vaccine, which needs to be refrigerated at -70C (-94F). Ten million doses are expected in the UK by the end of the year and patients need two each. Care home residents and their carers will be first in line to be vaccinated, the government’s Joint Committee on Vaccination and Immunisation (JCVI) has confirmed. Speaking to Sky News this morning, health secretary Matt Hancock said the approval of the vaccine is “fantastic news”. He added: “The MHRA – the fiercely independent regulator – has clinically authorised the vaccine for rollout. “The NHS stands ready to make that happen so from early next week we will start the programme of vaccinating people against COVID-19 here in this country. “As we know from earlier announcements, this vaccine is effective, the MHRA have approved it as clinically safe and we have a vaccine, so it’s very good news.”

table: How COVID-19 vaccines ordered by the UK compare © Other How COVID-19 vaccines ordered by the UK compare Mr Hancock added there would be “three modes of delivery” of the vaccine. “The first is hospitals themselves, which of course we’ve got facilities like this,” he said. “50 hospitals across the country are already set up and waiting to receive the vaccine as soon as it’s approved, so that can now happen. “Also vaccination centres, which will be big centres where people can go to get vaccinated. They are being set up now.” Mr Hancock said the military are involved in the logistics of the vaccine rollout and 800,000 jabs are being brought from Belgium. An effective vaccine is seen as the main weapon in fighting the pandemic, which has claimed more than 1.4 million lives worldwide. Pfizer and BioNTech reported final trial results on 18 November that showed its vaccine was 95% effective in preventing COVID-19, with no major safety concerns. Sky News’ science correspondent Thomas Moore said: “It’s going to be tricky to rollout but nevertheless this is really good news. “It’s two doses per person so that’s an awful lot of people who could be vaccinated. “Because it needs to be stored at -70C (-94F), it’s going to be shipped in dry ice to hospital centres that have these special cryo-freezers.”

Yellen: We are facing historic crisis

U.S. President-elect Joe Biden’s treasury secretary nominee Janet Yellen said on Tuesday the country is facing a historic crisis from the pandemic and the subsequent economic fallout.

Dec 1 (Reuters) – President-elect Joe Biden’s treasury secretary nominee Janet Yellen said on Tuesday the United States is experiencing a historic crisis due to the coronavirus pandemic and its economic fallout that requires urgent action to avert a “self-reinforcing” downturn. Yellen, who previously served as U.S. Federal Reserve Chair, spoke at an event in Delaware where Biden formally introduced his top economic policy advisers as he prepares to take office on Jan. 20 amid a battered economy and large-scale job losses. “It’s an American tragedy and it’s essential that we move with urgency. Inaction will produce a self-reinforcing downturn, causing yet more devastation,” Yellen said. Yellen said the pandemic has disproportionately impacted the most needy Americans. Yellen said it is important to make sure the economic recovery leaves out no one as she pledged to “find collective purpose to control the pandemic and build our economy back better than before.” Earlier on Tuesday, outgoing Treasury Secretary Steven Mnuchin urged the U.S. Senate to support $300 billion in new grants to small businesses to keep them from failing amid the intensifying public health crisis. “These businesses cannot wait two or three months” for aid, Mnuchin said. Mnuchin defended his action to end some Fed lending programs, a move that will limit Yellen’s options in backstopping credit markets if she is confirmed to the post by the Senate after being nominated by Biden. Mnuchin said his action was not an “economic decision” but one based on the aid law passed by Congress. Meanwhile, deadlocked negotiations over a new coronavirus economic aid package picked up some picked up momentum, as a bipartisan group of lawmakers floated a $908 billion relief proposal. Senate Majority Leader Mitch McConnell also said he was circulating among his fellow Republicans the outlines of relief legislation that President Donald Trump would be willing to sign into law during his remaining weeks in office. “I think we all know that after the first of the year there’s likely to be a discussion about some additional package of some size,” proposed by the new Biden administration, McConnell said. It remains unclear whether Yellen would be the main negotiator for future coronavirus aid, a role that Mnuchin played this year for Trump’s administration in talks with House of Representatives Speaker Nancy Pelosi. Yellen and other Biden advisers have expressed support for government stimulus to maximize employment, reduce economic inequality and help women and minorities, who have been hurt disproportionately by the economic downturn. “I pledge as treasury secretary to work every day towards rebuilding their dream for all Americans,” Yellen said. “To the American people, we will be an institution that wakes up every morning thinking about you, your jobs, your paychecks, your struggles, your hopes, your dignity and your limitless potential.”

Americans are choosing death over deprivation

This past week, millions of Americans joined together in total defiance of all public health advice for another round of infecting and killing their loved ones, while ensuring that the nation’s medical professionals will face several more months of risky, grueling, emotionally draining labor trying to keep a country full of heedless jerks and credulous conspiracy-mongers alive. Many doctors, nurses, and hospital staff are increasingly hopeless and disillusioned. Gone are the 7’oclock cheers and “Thank you essential workers” signs in every window. That fleeting solidarity has been replaced by a cold, selfish indifference to the staggering and seemingly pointless sacrifices these heroic workers continue to make on our behalf. And many of them are wondering how much longer they can keep it up. Never has this been more clear than it was over the long Thanksgiving weekend. While many Americans did the sensible — if heart-wrenching — thing and stayed home or limited their gatherings to small, pre-existing “pods,” more than 8 million people traveled through airports the day before Thanksgiving. In one poll, 40 percent of respondents told researchers they were planning on attending a large, in-person gathering. All of this while a record 90,000 people were already hospitalized with COVID-19, and public health professionals begged people to stay home so as not to exacerbate the problem. How can people do this, knowing that their actions risk their own lives and the lives of others? It would be one thing if the incredible, worldwide scientific effort to create a vaccine for this terrible virus was failing and there was no hope on the bleak horizon. But it looks like multiple vaccines will be deployed beginning next month, with the possibility of a return to some kind of normalcy by the end of next year. The end of this thing is now tantalizingly in sight. This is not to minimize what people have been through, or the misery that awaits those who hunker down for the winter, still cruelly shorn of nearly all social contact and ordinary joys. But the reality is that many Americans are now consciously choosing to spread death and suffering over finding the strength to endure for a few more months. And they aren’t just harming themselves: They are putting unimaginable strain on the country’s health-care system, as burned out doctors, nurses, and staff ask themselves why they are martyring themselves on behalf of such a venal society. One viral immunologist told me that, “I feel upset with these folks because this is inevitably going to cause more death and harm and not just to them but others who did stay home and followed guidelines.” He added that much of the blame rests with national and state political leaders determined to play down the gravity of the problem so they could rush economic re-openings. A palliative medical counselor said that the staff at her facility “is wonderful but furious when it is the patients’ reckless behavior that puts them in the ICU for COVID.” Fury gives way to exhaustion and resignation. “They still provide superhuman care,” she says, “but it’s only human to be frustrated.” Health-care workers are not in the army. No one is forcing them to suit up and plunge themselves into another 16-hour shift of watching a deadly virus suffocate people to death. There is no law that says they must carry on even when COVID patients show up convinced the whole thing was a plot designed to harm President Trump’s re-election prospects. Health-care providers know perfectly well that a lot of the patients they are treating scoffed at the danger and shrugged off expert guidelines and did whatever they wanted anyway.

This kind of behavior is evil, selfish, and cartoonishly destructive. It fills me with incoherent rage. This is a country full of people who have completely lost their way. One of the most infuriating things about it all is that the gob-smackingly selfish actions of your friends and neighbors will serve to counteract the sacrifices of those who have spent the past 9 months trying to do the right thing.

It means your friends, parents, and grandparents could get infected with this disease and then die from it, all because millions of your selfish fellow citizens plainly lacked the fortitude to weather temporary adversity, and because the depraved ghouls currently in charge of the federal government refused to spend the money needed to help the riskiest places — bars, restaurants, and gyms — stay closed and financially whole. We know now where this is headed over the next few months. Hospitals will be taxed beyond capacity, spiking the death rate from COVID and delaying or canceling care for tens of thousands of others. There will be mobile morgues and mass graves and countless Zoom funerals and an entire generation of health-care workers with permanent emotional trauma. People will show up to the ER after car accidents and heart attacks and allergic reactions and die waiting. The overall coronavirus death toll, now at more than 266,000, will surpass 400,000 or more by March and could ultimately reach half a million or more. The economic fallout could last years. So much of this suffering will ultimately have been needless. Tens of thousands will perish weeks or even days before they could have been saved. More and more frontline workers will succumb. And it is all because so many of our fellow citizens have revealed themselves to be both pathetic and decadent. It is truly hard to believe that the millions of people who are too weak-willed to go a year without sitting down for a meal inside a restaurant are the descendants of the brave men and women who fought and won World War II with five years of painful sacrifices and solidarity. A lot of Americans circa 2020 wouldn’t have made it three weeks past Pearl Harbor before protesting rationing and demanding our surrender to the Axis powers, and they deserve neither our sympathy nor the extraordinary heroism of doctors, nurses, and staff in hospitals and care homes across the country.

World’s Largest Vaccine Maker Denies Trial Volunteer’s Illness Claims

https://youtu.be/nOBNMkXy-lw
World’s Largest Vaccine Maker Denies Trial Volunteer’s Illness Claims.
The Serum Institute of India Ltd. denied allegations that a Covid-19 trial volunteer in India suffered serious side effects from a vaccine developed by AstraZeneca Plc and Oxford University, and said it would take legal action over the claims.
Serum, the world’s largest vaccine manufacturer, is conducting trials of AstraZeneca’s shot locally as part of a manufacturing agreement. It’s being sued by a volunteer in the southern Indian city of Chennai, who said he suffered from serious neurological and psychological symptoms after taking the experimental shot, according to news reports. The volunteer is seeking compensation of 50 million rupees ($676,000). Serum said in a statement on Sunday that the volunteer’s illness had nothing to do with the vaccine and that it would counter-sue. The incident adds to the global attention on AstraZeneca’s Covid-19 vaccine, a fast-moving shot that’s one of three western efforts which could be approved before the end of the year. Development that usually takes years has been compressed into months due to the urgency of the pandemic, and questions are growing over whether safety has been compromised in the rush. The volunteer in India was given the Covishield vaccine on Oct. 1 and had to spend time in an intensive care unit for the side effects that followed, said reports. In response, Serum said in an emailed statement over the weekend that the allegations were “malicious and misconceived” and that the volunteer had been told his symptoms were independent of the vaccine trial. Novavax CEO on delayed U.S. Covid-19 vaccine trial “There is absolutely no correlation with the vaccine trial and the medical condition of the volunteer,” the statement said, without elaborating on how this conclusion was arrived at. Serum has not been the only Covid-19 vaccine trial in India to face questions over safety. Last week, local media outlets reported that a participant in trials for a shot developed by local drugmaker Bharat Biotech International Ltd. was hospitalized after an adverse reaction, but that this was not disclosed to subsequent volunteers. Bharat did not immediately respond to a request for comment on Monday, which is a public holiday in India. India, which has the world’s second-biggest coronavirus outbreak after the U.S., is looking to vaccines to help slow the virus’s spread after containment efforts proved largely ineffective. On Saturday, Prime Minister Narendra Modi traveled across the country to meet officials at Serum Institute, Bharat Biotech and a third developer, Cadila Healthcare Ltd., to check on the status of their shots. Serum has already produced millions of doses. Chief Executive Officer Adar Poonawalla told reporters Saturday the company expects to apply for emergency authorization within two weeks.

Fauci: We may see surge upon surge in COVID cases

The nation’s top infectious disease expert said Sunday that the U.S. may see “surge upon a surge” of the coronavirus in the weeks after Thanksgiving, and he does not expect current recommendations around social distancing to be relaxed before Christmas. Meanwhile, in a major reversal, New York City Mayor Bill DeBlasio said the nation’s largest school system will reopen to in-person learning and increase the number of days a week many children attend class. The announcement came just 11 days after the Democratic mayor said schools would shut down because of rising COVID-19 cases. “We feel confident that we can keep schools safe,” he said. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told ABC’s “This Week” that the level of infection in the U.S. would not “all of a sudden turn around.” “So clearly in the next few weeks, we’re going to have the same sort of thing. And perhaps even two or three weeks down the line … we may see a surge upon a surge,” he said. Fauci addressed the school issue, saying that spread “among children and from children is not really very big at all, not like one would have suspected. So let’s try to get the kids back, but let’s try to mitigate the things that maintain and just push the kind of community spread that we’re trying to avoid,” he said. Fauci also appeared on NBC’s “Meet the Press,” where he made similar remarks, adding that it’s “not too late” for people traveling home after Thanksgiving to help curb the virus by wearing masks, staying distant from others and avoiding large groups of people.

The number of new COVID-19 cases reported in the United States topped 200,000 for the first time Friday, according to data from Johns Hopkins University. Since January, when the first infections were reported in the U.S., the nation’s total number of cases has surpassed 13 million. More than 265,000 people have died.

Fauci said the arrival of vaccines offers a “light at the end of the tunnel.” This coming week, the Advisory Committee on Immunization Practices will meet with the Centers for Disease Control and Prevention to discuss a rollout of the vaccine, he said. He added that President-elect Joe Biden should focus on distributing vaccines in an “efficient and equitable way.” Fauci also said he planned to push the new administration for a rigorous testing program. Health care workers will likely be among the first to get the vaccine, with the first vaccinations happening before the end of December, followed by many more in January, February and March, he said. “So if we can hang together as a country and do these kinds of things to blunt these surges until we get a substantial proportion of the population vaccinated, we can get through this,” Fauci said.

Other experts agreed that the coming weeks would be difficult, especially since so many traveled over the holiday and held in-person dinners indoors.

Dr. Deborah Birx, the White House coronavirus response coordinator, said Sunday on CBS’ “Face the Nation” that Americans who traveled this past week should try to avoid people over 65. She said that those who were around others for Thanksgiving “have to assume that you were exposed and you became infected and you really need to get tested in the next week.” Meanwhile, a busy travel weekend continued, despite warnings for Americans to stay close to home and limit their holiday gatherings. Aside from the Thanksgiving holiday itself, anywhere from 800,000 to more than 1 million travelers made their way through U.S. airport checkpoints on any day during the past week, according to Transportation Security Administration statistics. That’s a far cry from the 2.3 to 2.6 million seen daily last year. But it far surpasses the number of travelers early in the pandemic, when daily totals fell below 100,000 on some spring days. More COVID-19 restrictions were in store for California starting Monday. Los Angeles County will impose a lockdown calling for its 10 million residents to stay home. Santa Clara County, which includes San Jose, is banning all high school, collegiate and professional sports and imposing a quarantine for anyone traveling into the region from more than 150 miles away.

The Risks of Rushing a COVID-19 Vaccine

Ten corona vaccine candidates are now in late-stage trials. The world is already celebrating what could be the breakthrough in fighting COVID-19. Pharmaceutical companies are also cheering. The public sector has invested billions more in development. but it’s the private sector that will rake in the cash. Under existing agreements, they control the price and get the profits. Pharma firms say development is expensive

The excitement and enthusiasm for a COVID-19 vaccine by the end of 2020 is both palpable and understandable. We all hope for a rapid end to the pandemic and an effective vaccine would be a surefire solution. But there are risks that come with a fast-tracked vaccine delivered end of this year, not the least of which are the risks related to the safety of the vaccine itself.

Telescoping testing timelines and approvals may expose all of us to unnecessary dangers related to the vaccine. While preclinical trials to evaluate the potential safety and efficacy of vaccine candidates are likely to include tens of thousands of patients, it is still unclear whether that number will be large enough and a trial will last long enough to evaluate safety for a drug that would be administered to so many.

The US alone plans to vaccinate hundreds of millions of people with the first successful candidate. One serious adverse event per thousand of a vaccine given to 100 million people means harm to 100,000 otherwise healthy people. Aside from questions of safety that attend any vaccine, there are good reasons to be especially cautious for COVID-19. Some vaccines worsen the consequences of infection rather than protect, a phenomenon called antibody-dependent enhancement (ADE). ADE has been observed in previous attempts to develop coronavirus vaccines. To add to the concern, antibodies typical of ADE are present in the blood of some COVID-19 patients. Such concerns are real. As recently as 2016, Dengavxia, intended to protect children from the dengue virus, increased hospitalizations for children who received the vaccine. Questions also arise around the efficacy of a potential vaccine. The little we know of the current generation of COVID-19 vaccines raises serious questions regarding their ability to protect people from infection. We know all the candidates tested to date in non-human primates failed to protect any of the monkeys from infection of the nasal passages, the primary route of human infection. Failure to protect entirely from infection fits with all we know about attempts to protect monkeys from two other deadly coronaviruses, those that cause SARS and MERS. As many of the most serious COVID symptoms do not appear until late in the disease course, sometimes four to five weeks following exposure, there is a possibility that we will not have sufficient time to judge efficacy of a new vaccine, even by the lower standard of symptom amelioration. An effective COVID-19 vaccine also faces several hurdles beyond our control. The older we get the poorer our ability to respond to vaccines. Resistance to vaccination begins early at age 30 and becomes progressively more profound with time. That is especially troubling as those over 60 are the population most at risk. Vaccination of the elderly may sometimes succeed by administering repeated doses and by increasing the potency of the vaccine with powerful adjuvants. But these adjuvants can be especially risky for the very old.

It seems a folly then to rush our way towards a vaccine in 2020 if it is likely to have only limited benefit to the population most in need and may put otherwise healthy people at risk. The risk goes far beyond the dangers a COVID vaccine alone may hold.

Public support for vaccines in general is already an issue. Trust in other lifesaving vaccines will be eroded even further if a COVID vaccine goes wrong and many more people—children especially—will be at risk if vaccination rates fall. Yes, we are all increasingly longing for an end to the outbreak. But a safe vaccine, effective for all those at risk, is worth the wait, especially when we have other solutions in hand. We already know from the experience of countries in Asia that the epidemic can be stopped in its tracks with basic public health measures: widespread testing, contact tracing, and mandatory controlled quarantine—not necessarily in a dismal public health facility as many imagine, but in our own homes with virtual supervision or in a hotel environment. These efforts alone could bring new infections down to almost zero within just weeks.

 

There is no doubt we need an urgent end to the pandemic. Economies around the world are crashing. Governments are piling up trillions of dollars in debt. And, in the US alone, tens of millions are without work or income. But there are still costs that are too great, even when compared to such numbers. When we have solutions to the pandemic in hand we cannot risk the potential lives lost of rushing a COVID vaccine to market.

AstraZeneca CEO expects to run new global trial of COVID-19 vaccine

The news comes as AstraZeneca faces questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and EU regulatory approval.

Several scientists have raised doubts about the robustness of results released on Monday showing the experimental vaccine was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.Soriot said he did not expect the additional trial to delay British and European regulatory approvals.Asked about the Bloomberg report, an AstraZeneca spokesman said there was strong merit in continuing to investigate the half-dose/full dose regimen. Any further insights from the data would be added to those from existing trials that are being prepared for regulatory submission, he said. Running an additional trial might not be too much of a complication for the British drugmaker in the race to develop a vaccine to help tame the pandemic, which has killed more than a million people and roiled the global economy. Helen Fletcher, professor of immunology at the London School of Hygiene & Tropical Medicine, said another trial would not necessarily delay getting a green light as efficacy in the higher dose regime still met the World Health Organization’s target. It was not unusual to run new studies on approved vaccines, she said. The vaccine is one of three that could get approved before the end the year. This month, Pfizer and Moderna reported that their vaccines were about 95% effective in preventing illness, setting the bar sky-high.Even so, the AstraZeneca shot developed with Oxford University is cheaper to make, easier to distribute and faster to scale up than its rivals. Britain on Friday asked its medicine regulator to assess if the vaccine candidate met rigorous safety standards with a view for temporary supply, a step towards beginning a roll-out of the vaccine before the end of the year.AstraZeneca expects 4 million doses to be available in Britain by the end of next month. A peer-reviewed analysis of data from the new trial will be published in a medical journal in coming weeks. The European Medicines Agency did not immediately respond to requests for comment.AstraZeneca told Reuters earlier on Thursday that administering of the half dose had been reviewed and approved by independent data safety monitors and the British regulator, adding that the regulator publicly confirmed there was “no concern”. Clearance from the U.S. Food and Drug Administration (FDA) may take longer, though, because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, especially given the questions over the results, Soriot said.AstraZeneca research chief Mene Pangalos told Reuters on Monday the firm would start discussions with the FDA to change the design of its trial to add the more-effective dosage regime.Authorisation in some countries is still expected before the end of the year.Astrazeneca has struck deals to supply the vaccines in several countries, including 120 million doses to Japan and 85 million doses to Australia. Australian Prime Minister Scott Morrison, talking to media, expressed confidence about the vaccine, which is being manufactured by the country’s biomedical giant CSL Ltd.The Serum Institute of India is conducting trials of the vaccine there. “Even the lowest efficacy results are at 60-70%, making it a viable vaccine against the virus,” the institute said in a statement, adding that the trials were running smoothly.

US adds 155,596 coronavirus cases, 1,189 deaths

Please view the above 8 minute video.it graphs the spreading plague

United States Coronavirus Cases:

13,610,357

Deaths:

272,254

Recovered:

8,041,239
Closed Cases
8,313,493
Cases which had an outcome:

8,041,239 (97%)

Recovered / Discharged
272,254 (3%)

San Francisco to impose curfew on Nov. 30

An increase in cases of COVID-19 has sent San Francisco into the purple level of California’s color-coded reopening plan, officials announced on November 28. As a result, the county must now join most of the rest of the state’s limited stay-at-home order, which requires that “non-essential work, movement, and gatherings,” including outdoor dining, cease between 10 p.m. and 5 a.m. from November 30 until December 21. This isn’t a surprise to city and county health officials, who warned on November 20 that the region was on track to move from the red (“substantial risk” of COVID-19 exposure) to the most restrictive, purple tier (“widespread risk”) in coming days. Counties that enter the purple tier, Gov. Gavin Newsom announced on November 19, must follow a state-mandated shelter-in-place order “designed to reduce opportunities for disease transmission,” including the weeks-long curfew. “Activities conducted during 10 PM to 5 AM are often non-essential and more likely related to social activities and gatherings that have a higher likelihood of leading to reduced inhibition and reduced likelihood for adherence to safety measures like wearing a face covering and maintaining physical distance,” the state said in a statement regarding the curfew, which now applies to 99.1 percent of the state’s population, including every county in the Bay Area but Marin (which, as of publication time, remains red). You can see a full list of tier assignments here.

According to the announcement of the shutdown from the city, customers must leave restaurants by 10 p.m., but restaurants may remain open for takeout or delivery. Other non-essential businesses must close and gatherings must cease, but businesses like grocery and convenience stores may remain open, with a capacity limit of 50 percent.

“This is the most aggressive surge SF has seen to date,” Breed says, as “we’re currently averaging 118 new cases per day compared to 73 per day in the first week of November…For the week of November 16th, we had 768 diagnosed cases compared to 217 diagnosed cases the week of October 12th.”

Breed’s remarks follow those of San Francisco Health Director Dr. Grant Colfax, who said on November 27 that the number of San Franciscans that have tested positive for COVID-19 “in the last 4 weeks has increased 265 percent.” It’s also expected — but still tough — news for the city’s restaurants, many of which rely on dinner service to remain afloat. In a statement, the Golden Gate Restaurant Association, the lobbying group for San Francisco’s dining industry, says that the 10 p.m. curfew means that “although outdoor dining in San Francisco will remain open…restaurants will in reality not be able to take reservations past 8 or 8:30 p.m., therefore severely limiting their ability to do business.” “Although our foremost concern remains with the health and well-being of our community, we expect immediate negative effects to our industry and continue to call on our city leaders to help us survive by making financial relief available for our restaurants and our employees,” the GGRA says. “We also call on Congress to pass a relief package that includes the Restaurants Act and additional PPP funding immediately.”

Black Friday shopping in stores craters 52% during pandemic as e-commerce sales surge

  • Traffic at stores on Black Friday fell by 52.1% compared with last year, according to preliminary data from Sensormatic Solutions.
  • “Shoppers are spreading out their shopping throughout the holiday season because of concerns about social distancing and the pandemic,” said Brian Field.
  • Online spending on Black Friday surged 21.6% to hit a new record, according to data from Adobe Analytics.

Traffic at stores on Black Friday fell by 52.1% compared with last year, as Americans by and large eschewed heading to malls and queuing up in lines for shopping online, according to preliminary data from Sensormatic Solutions. For the six key weeks of the holiday season this year, traffic in retail stores is expected to be down 22% to 25% year over year, an earlier forecast by Sensormatic Solutions said. “We knew Black Friday [traffic] was going to be down, we just didn’t know how much it was going to be down,” said Brian Field, a senior director of global retail consulting at Sensormatic Solutions. “Shoppers are spreading out their shopping throughout the holiday season because of concerns about social distancing and the pandemic.” The Covid pandemic has pushed a record number of consumers to shop online, instead, as retailers place many of their top holiday doorbuster deals online and encourage shoppers to buy on the web and then pick up purchases curbside. The Centers for Disease Control and Prevention also recommended that Americans shop online the day after Thanksgiving.

Many malls looked bleak, and parking lots were more empty than full, across much of the country during the early hours of the morning Friday.

Some reported traffic picking up later in the day, especially at outlet and open-air shopping centers, as some consumers felt more comfortable heading out. The warmer weather that blanketed much of the country also helped. The typical peak time for shopping on Black Friday remained the same this year, hitting at about 2 p.m., Sensormatic Solutions said. On Thanksgiving Day, when many retailers including Walmart and Target closed their stores this year due to the pandemic, traffic dropped 94.9% year over year, according to the firm. Week-to-date, traffic is down 45.2% across the U.S. “Black Friday this year, from a traffic impact perspective, looked a lot like a typical Saturday after a Black Friday,” Field said.